证券代码：300813 证券简称：泰林生物 公告编号：2025-028 关于变更注册资本并修订《公司章程》的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 浙江泰林生物技术股份有限公司（以下简称"公司"）第四届董事会第七次 会议于 2025 年 4 月 24 日召开，会议审议通过了《关于变更注册资本并修订〈公 司章程〉的议案》。现将有关情况公告如下： 一、公司注册资本变更情况 经中国证券监督管理委员会证监许可〔2021〕2258 号同意注册，公司于 2021 年 12 月 28 日向不特定对象发行 2,100,000 张可转换公司债券，并于 2022 年 1 月 19 日起在深交所挂牌交易，债券简称为"泰林转债"，债券代码为"123135"。 二、公司章程修订情况 浙江泰林生物技术股份有限公司 "泰林转债"自 2022 年 7 月 4 日开始转股，并于 2024 年 11 月 21 日触发 有条件赎回条款。经公司董事会审议，决定按照债券面值加当期应计利息的价格 赎回在赎回登记日（2024 年 12 月 12 日）收市后登记在册的全部"泰林转债"。 "泰林 ...

浙江泰林生物技术股份有限公司 证券代码：300813 证券简称：泰林生物 公告编号：2025-031 关于拟与杭州富春湾新城管理委员会签订高性能过滤器及 配套功能膜产业化项目合同书暨对外投资的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1.本项目不构成关联交易，不构成重大资产重组事项。本次投资事项尚需股 东大会审议批准后方可生效，协议能否生效尚存在不确定性。 2.本次项目用地需按照国家现行法律法规及地方政策规定的用地程序办理， 通过招标、拍卖或挂牌出让方式取得，土地使用权能否竞得、土地使用权的最终 成交价格及取得时间存在不确定性。 3.本次投资项目尚需发改、环保等部门审批，存在不确定性；项目的各项数 据均为初步规划数据，不代表公司对未来盈利的任何预测或承诺，最终实际投资 金额具有不确定性。 4.本次项目建设、投产及生产经营需要一定的时间，存在一定的不确定性， 同时，受宏观经济、行业政策、市场环境变化等因素的影响，可能存在如未能按 期建设完成、未能达到预期收益的风险。 5.本协议的签署对公司当期经营业绩和财务状况不构成重大影响，对公司长 期 ...

一、主要会计数据和财务指标 | 报告期指标 | 2024年年报 | 2023年年报 | 本年比上年增减(%) | 2022年年报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | 0.1200 | 0.1800 | -33.33 | 0.7400 | | 每股净资产（元） | 0 | 5.33 | -100 | 6.94 | | 每股公积金(元) | 3.47 | 1.79 | 93.85 | 2.56 | | 每股未分配利润(元) | 2.07 | 2.29 | -9.61 | 3.05 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 3.49 | 2.7 | 29.26 | 3.74 | | 净利润(亿元) | 0.13 | 0.2 | -35 | 0.8 | | 净资产收益率(%) | 1.94 | 3.04 | -36.18 | 13.25 | 数据四舍五入，查看更多财务数据>> 二、前10名无限售条件股东持股情况 前十大流通股东累计持有： 3052.99万股，累计占流通股比： 40.15%，较上期变化： 609 ...

证券代码：300813 证券简称：泰林生物 公告编号：2025-033 浙江泰林生物技术股份有限公司 关于召开 2024 年年度股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、召开会议的基本情况 1．股东大会届次：2024年年度股东大会 2．股东大会的召集人：公司董事会 3．会议召开的合法、合规性：经公司第四届董事会第七次会议审议通过， 决定召开2024年年度股东大会，召集程序符合有关法律、行政法规、部门规章、 规范性文件、深圳证券交易所业务规则和《公司章程》等的规定。 4．会议召开时间： （1）现场会议召开时间：2025年5月19日（星期一）14:00。 （2）网络投票时间：2025年5月19日。 其中，通过深圳证券交易所交易系统进行网络投票的时间为2025年5月19日 9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券交易所互联网系统投票的 具体时间为2025年5月19日9:15-15:00。 5．会议的召开方式：本次股东大会采用现场投票与网络投票相结合的方式。 （1）现场投票：股东本人出席现场会议或者通过授 ...

浙江泰林生物技术股份有限公司监事会 综上，本次应作废已授予尚未归属的限制性股票数量合计为 1,507,584 股。 监事会认为，公司本次作废部分已授予尚未归属的限制性股票事项符合《管 理办法》《上市规则》《自律监管指南》等法律法规以及《激励计划（草案）》的 有关规定，审议程序合法合规，不存在损害公司及全体股东利益的情况。因此， 监事会同意作废上述激励对象已获授尚未归属的限制性股票。 浙江泰林生物技术股份有限公司监事会 2025 年 4 月 24 日 （以下无正文，为审核意见签字页） 关于作废 2022 年限制性股票激励计划部分已授予尚未归属 的限制性股票的审核意见 浙江泰林生物技术股份有限公司（以下简称"公司"）于 2025 年 4 月 25 日 召开第四届监事会第七次会议。根据《上市公司股权激励管理办法》（以下简称 "《管理办法》"）、《深圳证券交易所创业板股票上市规则》（以下简称"《上市规 则》"）《深圳证券交易所创业板上市公司自律监管指南第 1 号——业务办理》（以 下简称"《自律监管指南》"）等有关法律、法规和规范性文件以及《浙江泰林生 物技术股份有限公司（章程）》（以下简称"《公司章程》"）《浙江泰 ...

证券代码：300813 证券简称：泰林生物 公告编号：2025-018 浙江泰林生物技术股份有限公司 第四届监事会第七次会议决议公告 经与会监事审议，会议通过如下议案： 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、监事会会议召开情况 浙江泰林生物技术股份有限公司（以下简称"公司"）第四届监事会第七次会议 于 2025 年 4 月 14 日以电话、书面送达等形式发出通知，并于 4 月 24 日在公司会议 室以现场举手表决的方式召开。会议应出席监事 3 名，实际出席监事 3 名。本次会 议由胡美珠女士召集和主持。 本次会议的召开符合《中华人民共和国公司法》《公司章程》及有关法律、行政 法规的要求，会议合法、有效。 二、监事会会议审议情况 （一）审议通过《2024 年年度报告及其摘要》 经审核，监事会认为，董事会编制和审核公司 2024 年年度报告的程序符合法律、 行政法规和中国证监会的规定，报告内容真实、准确、完整地反映了公司的实际情况， 不存在任何虚假记载、误导性陈述或者重大遗漏。 具体内容详见公司在中国证监会指定创业板信息披露网站巨潮资讯网 （http ...

证券代码：300813 证券简称：泰林生物 公告编号：2025-017 浙江泰林生物技术股份有限公司 第四届董事会第七次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 浙江泰林生物技术股份有限公司（以下简称"公司"）第四届董事会第七次 会议于 2025 年 4 月 14 日以电话、书面送达等形式发出通知，并于 4 月 24 日在 公司会议室以现场举手表决的方式召开。会议应出席董事 7 名，实际出席董事 7 名。本次会议由叶大林先生召集和主持，公司董事会秘书、监事及高管列席会议。 本次会议的召开符合《中华人民共和国公司法》《公司章程》及有关法律、 行政法规的要求，会议合法、有效。 二、董事会会议审议情况 经与会董事审议，会议通过如下议案： （一）审议通过《2024 年年度报告及其摘要》 经审核，董事会通过了《2024 年年度报告及其摘要》。 具体内容详见公司在中国证监会指定创业板信息披露网站巨潮资讯网 （http://www.cninfo.com.cn）发布的《2024 年年度报告全文及其摘要》。 本议案已经公司审计委员会审 ...

证券代码：300813 证券简称：泰林生物 公告编号：2025-022 一、审议程序 浙江泰林生物技术股份有限公司（以下简称"公司"）于 2025 年 4 月 24 日召 开第四届董事会独立董事 2025 年第一次专门会议、第四届董事会第七次会议以及第 四届监事会第七次会议，审议通过了《关于 2024 年度利润分配方案的议案》。本议案 尚需提交公司 2024 年度股东大会审议。 浙江泰林生物技术股份有限公司 2024 年度利润分配方案 1.独立董事专门会议意见 经审议，独立董事认为，公司提议的 2024 年度的利润分配方案，综合考虑了公 司正常经营状况、未来发展和股东合理回报等因素，符合公司的客观情况和《公司章 程》及有关法律法规的有关规定，不存在损害公司及股东特别是中小股东的利益的情 况，有利于促进公司的持续、稳定发展。我们一致同意该议案，并同意将该议案提交 公司董事会审议。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 2.董事会意见 经审核，董事会通过了《关于 2024 年度利润分配方案的议案》，同意拟以实施权 益分派股权登记日总股本（扣除回购专用账户 ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥66,938,979.30, a decrease of 16.33% compared to ¥80,006,616.11 in the same period last year[5] - The net profit attributable to shareholders was ¥3,528,154.63, down 39.93% from ¥5,873,080.66 year-on-year[5] - Basic and diluted earnings per share were both ¥0.03, a decrease of 40.00% from ¥0.05 in the same period last year[5] - Net profit for the period was ¥3,327,916.52, down from ¥5,541,204.91, reflecting a decrease of approximately 40.0% year-over-year[21] - Total operating revenue decreased to ¥66,938,979.30 from ¥80,006,616.11, representing a decline of approximately 16.4% year-over-year[20] - Total operating costs decreased to ¥62,864,064.42 from ¥77,318,177.90, a reduction of about 18.6% year-over-year[20] Cash Flow - The net cash flow from operating activities was -¥10,737,521.27, representing a decline of 70.53% compared to -¥6,296,392.84 in the previous year[5] - Operating cash inflow for the current period was $70,093,446.06, down from $80,315,376.79 in the previous period, representing a decrease of approximately 27.5%[24] - Net cash outflow from operating activities was -$10,737,521.27, compared to -$6,296,392.84 in the previous period, indicating a worsening of cash flow by approximately 70.5%[25] - Cash inflow from investment activities significantly increased to $472,400,165.74 from $176,994,526.02, marking an increase of approximately 167.5%[25] - Cash outflow from investment activities totaled $379,891,445.61, up from $176,608,235.15, reflecting an increase of approximately 114.5%[25] - The net increase in cash and cash equivalents for the current period was $54,449,822.06, contrasting with a decrease of -$5,893,231.99 in the previous period[25] Assets and Liabilities - Total assets at the end of the reporting period were ¥939,019,323.84, down 2.18% from ¥959,907,928.07 at the end of the previous year[5] - Total liabilities decreased to ¥115,440,823.90 from ¥139,178,386.25, a reduction of approximately 17.0% year-over-year[18] - The company's cash and cash equivalents decreased from RMB 264,872,528.62 to RMB 210,343,842.89, reflecting a decline of approximately 20.5%[16] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 11,553[10] - The largest shareholder, Ye Daling, holds 47.71% of the shares, totaling 57,824,000 shares[10] - The company reported a total of 1,208,000 shares held in the repurchase special account, accounting for 0.9967% of the total share capital[12] - The company has a total of 14,456,000 shares held by its largest shareholder, representing a significant portion of the total shares[12] Strategic Initiatives - The company plans to repurchase shares at a price not exceeding RMB 27.56 per share, with a total fund amount between RMB 20 million and RMB 40 million[13] - The company has initiated an employee stock ownership plan for 2025, which was approved by the board on March 11, 2025[14] - The company plans to focus on market expansion and new product development to drive future growth[23] Other Financial Metrics - The weighted average return on equity was 0.43%, down from 0.90% in the same period last year[5] - The company reported a decrease in other income by 63.20%, from ¥3,397,440.67 to ¥1,250,110.86, primarily due to reduced government subsidies[8] - The company's total equity attributable to shareholders increased slightly to ¥823,578,499.94 from ¥820,050,345.31, indicating a stable equity position[18] - Research and development expenses remained stable at ¥14,934,663.08 compared to ¥14,896,419.24, indicating continued investment in innovation[21] - Accounts receivable increased from RMB 43,546,552.81 to RMB 44,473,461.20, showing a growth of about 2.1%[16] - Inventory decreased from RMB 144,134,014.09 to RMB 141,018,169.49, indicating a reduction of approximately 2.2%[16] - The company reported a significant increase in cash flow from investing activities, which amounted to ¥92,508,720.13, a rise of 23,847.94% compared to ¥386,290.87 in the previous year[8]

Financial Performance - The company's operating revenue for 2024 was ¥348,998,253.03, representing a 29.33% increase compared to ¥269,856,059.81 in 2023[15]. - The net profit attributable to shareholders for 2024 decreased by 33.65% to ¥13,050,671.23 from ¥19,668,950.46 in 2023[15]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥6,680,101.87, down 40.55% from ¥11,236,498.92 in 2023[15]. - The net cash flow from operating activities surged by 1,176.30% to ¥24,656,614.19 from ¥1,931,884.51 in 2023[15]. - The total assets at the end of 2024 were ¥959,907,928.07, a decrease of 1.40% from ¥973,507,907.87 at the end of 2023[15]. - The net assets attributable to shareholders increased by 26.40% to ¥820,050,345.31 at the end of 2024 from ¥648,762,936.31 at the end of 2023[15]. - Total revenue for 2024 reached ¥348,998,253.03, representing a year-over-year increase of 29.33% from ¥269,856,059.81 in 2023[72]. - Revenue from the pharmaceutical industry accounted for 90.04% of total revenue, amounting to ¥314,245,411.71, with a year-over-year growth of 32.97%[72]. - The sales model through distributors generated ¥206,326,917.88, which is 59.12% of total revenue, showing a significant increase of 73.24% compared to the previous year[72]. - The company achieved operating revenue of ¥348,998,253.03 and a net profit attributable to shareholders of ¥13,050,671.23 during the reporting period[54]. Dividend and Profit Distribution - The company plans to distribute a cash dividend of 1 RMB per 10 shares (including tax) to all shareholders, with no bonus shares issued[3]. - The company plans to distribute a cash dividend of 1 yuan (including tax) for every 10 shares, totaling 11,999,121.90 yuan, which represents 100% of the total profit distribution[166]. - The total number of shares for the cash dividend distribution is based on 119,991,219 shares, with no stock dividends or capital reserve transfers[167]. - The company has not made any adjustments to its cash dividend policy during the reporting period, ensuring compliance with its articles of association and shareholder resolutions[167]. - The company’s profit available for distribution to shareholders is 115,685,721.27 yuan, indicating a healthy profit margin[167]. Research and Development - The company is focusing on the development of new products in the life sciences and biopharmaceutical equipment sector, aligning with national policies supporting emerging industries[25]. - The company has established a multi-level and multi-directional R&D organization, including the TaiLin Research Institute and various specialized R&D centers, to drive continuous innovation and product development[40]. - The company invests over 10% of its sales revenue annually in technology research and new product development[45]. - The company applied for a total of 11 invention patents and 25 utility model patents in 2024, indicating a strong focus on innovation and intellectual property development[65]. - R&D investment for 2024 is approximately ¥62.34 million, accounting for 17.86% of operating revenue, a decrease from 21.64% in 2023[85]. - The company has a strong R&D team, with over 50% of its personnel holding bachelor's degrees or higher, ensuring a solid foundation for continuous innovation[45]. - The company has launched 494 new online courses, totaling 12,272 hours of online learning, to enhance employee skills and organizational capabilities[67]. Product Development and Innovation - The company is positioned as a leader in the development and promotion of microbiological testing and contamination control instruments for the life sciences and pharmaceutical sectors[25]. - The company has developed a series of microbiological testing products for quality control in pharmaceuticals, food, and cosmetics, including sterile testing systems and microbial limit testing systems[28]. - The fully automated colony counting workstation significantly improves the efficiency and accuracy of microbial culture counting, providing broad application possibilities in biopharmaceuticals, healthcare, and food safety[29]. - The company has successfully developed NC membrane products for various in vitro diagnostic kits, applicable in fields such as drug testing and environmental monitoring[30]. - The company has launched multiple new products including the algae/two-insect intelligent analyzer and various biological indicators, enhancing its core competitiveness[55]. - The company has developed a smart fault diagnosis system for its main instruments, enhancing after-sales service efficiency and quality[50]. - The company has launched a new high-end intelligent bacterial collection instrument, enhancing product performance and quality to meet market demands[83]. Market Strategy and Expansion - The company is focused on expanding its market presence through innovative product development and strategic partnerships in the biopharmaceutical sector[36]. - The company is focusing on global expansion while optimizing its organizational structure and management mechanisms to enhance overall efficiency[57]. - The company intends to expand its overseas market presence, prioritizing Southeast Asia and Europe, and aims to increase the share of foreign trade in total sales[117]. - The company is addressing the risk of technical personnel turnover by improving work environments and providing development opportunities to retain key talent[120]. - The company plans to enhance its marketing strategy by expanding its customer base in healthcare and research sectors, increasing product coverage through regional distributors[122]. Corporate Governance and Management - The board of directors consists of 7 members, including 3 independent directors, ensuring compliance with legal and regulatory requirements[3]. - The company maintains independence from its controlling shareholders in terms of business, assets, personnel, and financial operations[130]. - The company has a structured salary system based on specific management roles and performance evaluation methods[146]. - The company has a comprehensive performance evaluation mechanism for senior management, focusing on professional skills and management capabilities[177]. - The company has a governance structure in place for its red-chip architecture, ensuring compliance and oversight[132]. - The company has established a performance evaluation and incentive system linking management compensation to business performance[129]. Financial Management and Investments - The company raised RMB 238.55 million through its initial public offering, with a net amount of RMB 197.94 million after deducting issuance costs[100]. - The company raised RMB 210 million through the issuance of convertible bonds, with a net amount of RMB 204.12 million after deducting issuance costs[100]. - The company has completed the investment project for the production base of 3,500 sets of microbial control and detection system equipment[101]. - The company has adjusted the use of previously raised funds, reallocating RMB 59.95 million to the cell therapy industrialization equipment manufacturing base project[100]. - The company has committed to strict adherence to share reduction commitments, with no violations reported[195]. Environmental and Social Responsibility - The company has implemented a distributed photovoltaic power generation project with a capacity of 610 kW, expected to generate over 600,000 kWh annually, saving over 200 tons of standard coal and reducing CO2 emissions by over 600 tons[189]. - The company has established various environmental management procedures to monitor and control waste and emissions effectively[187]. - The company emphasizes a profit distribution policy that balances reasonable returns to investors with sustainable development[188]. - The company maintains a strong focus on employee rights, providing a safe working environment and necessary social security benefits[188]. Risks and Challenges - The company recognizes risks from industry policy changes and plans to adapt its development strategy accordingly, focusing on market research and diversifying market strategies[119]. - Recent product launches targeting cell therapy and biodegradable testing may face challenges in market acceptance and competition, impacting expected project benefits[121]. - The actual controllers hold a combined 52.91% of the company's shares, which may lead to risks in management decisions affecting other shareholders[122].